Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01349959 | Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2025 | clinicaltrials |
| NCT01396655 | PET in Breast Cancer Receiving Neoadjuvant Chemotherapy(DA-PET) | completed | Phase 2 | 78 | Seoul National University HospitalOTHER | 0 | Apr 17, 2025 | clinicaltrials |
| NCT05555706 | Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | completed | Phase 2 / Phase 3 | 62 | Shanghai Jiaolian Drug Research and Development Co., LtdINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT01779206 | ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer(ADAPT) | completed | Phase 2 / Phase 3 | 4,936 | Women's Cancer Study Group GmbHOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT02091960 | A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer | completed | Phase 2 | 103 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Apr 4, 2025 | clinicaltrials |
| NCT05359783 | Sentinel Node Localization and Staging with Low Dose Superparamagnetic Iron Oxide(MAGSNOW) | completed | Phase 1 / Phase 2 | 50 | Vastra Gotaland RegionOTHER_GOV | 1 | Mar 28, 2025 | clinicaltrials |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 407 | Taiho Oncology, Inc.INDUSTRY | 13 | Mar 27, 2025 | clinicaltrials |
| NCT04494958 | Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer(PALBOBIN) | completed | Phase 1 / Phase 2 | 24 | Fundacion OncosurNETWORK | 1 | Mar 24, 2025 | clinicaltrials |
| NCT05137067 | A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents. | completed | Phase 2 | 90 | Optimal Health ResearchOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT01009788 | ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer | completed | Phase 2 | 63 | Steven J Isakoff, MD, PhDOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT01828021 | Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer | completed | Phase 2 | 25 | MacroGenicsINDUSTRY | 1 | Mar 13, 2025 | clinicaltrials |
| NCT02423603 | PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer(PAKT) | completed | Phase 2 | 71 | Queen Mary University of LondonOTHER | 6 | Mar 10, 2025 | clinicaltrials |
| NCT04499950 | Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study(A-NEW) | completed | Phase 2 | 53 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT01745965 | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.(ADAPT; T-DM1) | completed | Phase 2 | 380 | Women's Cancer Study Group GmbHOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT01781338 | Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer(ADAPT) | completed | Phase 2 / Phase 3 | 4,936 | Women's Cancer Study Group GmbHOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT01815242 | Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer(ADAPT) | completed | Phase 2 | 336 | Women's Cancer Study Group GmbHOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT01817452 | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol(ADAPT) | completed | Phase 2 | 220 | Women's Cancer Study Group GmbHOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT03250676 | Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | completed | Phase 1 / Phase 2 | 151 | Eisai Inc.INDUSTRY | 3 | Feb 25, 2025 | clinicaltrials |
| NCT02531932 | Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer | completed | Phase 2 | 64 | Amy TierstenOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03691493 | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis(ASPIRE) | completed | Phase 2 | 36 | Emory UniversityOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04432454 | Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation(ELAINEII) | completed | Phase 2 | 29 | Sermonix Pharmaceuticals Inc.INDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03703492 | Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS | completed | Phase 2 | 12 | University of Wisconsin, MadisonOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04079517 | Karolinska Interventional Study of Mammograhic Density (Karisma-1)(Karisma-1) | completed | Phase 1 / Phase 2 | 42 | Karolinska InstitutetOTHER | 0 | Feb 6, 2025 | clinicaltrials |
| NCT03333915 | Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 128 | BeiGeneINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT02694809 | The PROMISE Study: Duavee in Women With DCIS | completed | Phase 2 | 142 | Northwestern UniversityOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04294225 | Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer | completed | Phase 2 | 161 | Mayo ClinicOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT01084863 | Evaluate Safety, Efficacy and Pharmacokinetics(Compare) | completed | Phase 1 / Phase 2 | 143 | CelltrionINDUSTRY | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03562832 | Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP | completed | Phase 2 | 20 | Allarity TherapeuticsINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03504488 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | completed | Phase 1 / Phase 2 | 132 | BioAtla, Inc.INDUSTRY | 6 | Jan 15, 2025 | clinicaltrials |
| NCT03518606 | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours(MOVIE) | completed | Phase 1 / Phase 2 | 126 | UNICANCEROTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04603911 | RCT Comparing ESPB Solutions in Breast Surgery | completed | Phase 2 | 75 | Tufts Medical CenterOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT03847311 | Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients | completed | Phase 2 | 7 | University of ArizonaOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT01216176 | A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | completed | Phase 1 / Phase 2 | 71 | Joyce Marie Slingerland, MDOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT02203552 | Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer | completed | Phase 2 | 56 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT03950570 | ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 58 | Orinove, Inc.INDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT03084536 | PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery | completed | Phase 2 | 134 | Washington University School of MedicineOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT00470704 | Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer | completed | Phase 2 | 87 | Nancy Lin, MDOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT02993159 | Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast | completed | Phase 2 | 100 | Northwestern UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06265077 | Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients | completed | Phase 1 / Phase 2 | 58 | Noha MansourOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03206203 | Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | completed | Phase 2 | 106 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02491983 | Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer(PARSIFAL) | completed | Phase 2 | 486 | MedSIROTHER | 7 | Dec 9, 2024 | clinicaltrials |
| NCT02632045 | Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer(MAINTAIN) | completed | Phase 2 | 169 | Melissa K AccordinoOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT02708680 | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | completed | Phase 1 / Phase 2 | 89 | Syndax PharmaceuticalsINDUSTRY | 2 | Dec 4, 2024 | clinicaltrials |
| NCT03487666 | OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease | completed | Phase 2 | 45 | Georgetown UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04111510 | Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 6 | Yale UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03356860 | Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.(B-IMMUNE) | completed | Phase 1 / Phase 2 | 57 | Grand Hôpital de CharleroiOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 27, 2025source: clinicaltrials